Boehringer Ingelheim layoffs are a sign of dysfunctional Humira biosimilar market; Johnson & Johnson to buy Shockwave Medical for $13.1 billion

Taking stock of the drug industry, from the lab to the medicine chest

April 5, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Wikimedia Commons STAT+ | Boehringer Ingelheim layoffs are a sign of dysfunctional Humira biosimilar market Cyltezo can be substituted for Humira at the pharmacy counter without a doctor's permission, yet PBMs have been slow to adopt it. By John Wilkerson STAT+ | Johnson & Johnson to buy Shockwave Medical for $13.1 billion Shockwave Medical's device works to break down calcified plaque in the coronary and peripheral arteries using sonic pressure waves. By Lizzy Lawrence STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise Drug executives stayed true to their word. Oruka's CEO talks about financing. And hear about neoantigen cancer vaccine trials and a new use case for GLP-1s. By Allison DeAngelis and Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser